These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15750269)

  • 1. Patients preferences in chemotherapy for advanced non-small-cell lung cancer.
    Hirose T; Horichi N; Ohmori T; Kusumoto S; Sugiyama T; Shirai T; Ozawa T; Ohnishi T; Adachi M
    Intern Med; 2005 Feb; 44(2):107-13. PubMed ID: 15750269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer.
    Hirose T; Yamaoka T; Ohnishi T; Sugiyama T; Kusumoto S; Shirai T; Okuda K; Ohmori T; Adachi M
    Psychooncology; 2009 May; 18(5):483-9. PubMed ID: 18942662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.
    Silvestri G; Pritchard R; Welch HG
    BMJ; 1998 Sep; 317(7161):771-5. PubMed ID: 9740561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer chemotherapy decisions in older patients: the role of patient preference and interactions with physicians.
    Gironés R; Torregrosa D; Gómez-Codina J; Maestu I; Tenias JM; Rosell R
    Clin Transl Oncol; 2012 Mar; 14(3):183-9. PubMed ID: 22374421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer.
    Brundage MD; Davidson JR; Mackillop WJ
    J Clin Oncol; 1997 Jan; 15(1):330-40. PubMed ID: 8996160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
    Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
    BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public.
    Slevin ML; Stubbs L; Plant HJ; Wilson P; Gregory WM; Armes PJ; Downer SM
    BMJ; 1990 Jun; 300(6737):1458-60. PubMed ID: 2379006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
    Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
    Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more.
    Tamiya A; Naito T; Ono A; Ayabe E; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
    Lung Cancer; 2011 Feb; 71(2):173-7. PubMed ID: 20570388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support.
    Brundage MD; Feldman-Stewart D; Cosby R; Gregg R; Dixon P; Youssef Y; Mackillop WJ
    Patient Educ Couns; 2001 Nov; 45(2):149-57. PubMed ID: 11687329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
    Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
    Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer.
    Mohan A; Singh P; Kumar S; Mohan C; Pathak AK; Pandey RM; Guleria R
    Asian Pac J Cancer Prev; 2008; 9(4):557-62. PubMed ID: 19256738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Life Achieved by Carboplatin Plus Etoposide as Third-Line Chemotherapy Compared with Best Supportive Care in Non-Small Cell Lung Cancer Stage IIIB/IV.
    Maneechawakajorn J; Hathaisanguan S
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S175-81. PubMed ID: 27266233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
    Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
    J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.
    Chang AY; Kim K; Glick J; Anderson T; Karp D; Johnson D
    J Natl Cancer Inst; 1993 Mar; 85(5):388-94. PubMed ID: 8094467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gefitinib in the treatment of advanced non-small cell lung cancer].
    Yang L; Liu XY; Fang J; An TT; Wu MN
    Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):474-7. PubMed ID: 17152500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
    Langer CJ; O'Byrne KJ; Socinski MA; Mikhailov SM; Leśniewski-Kmak K; Smakal M; Ciuleanu TE; Orlov SV; Dediu M; Heigener D; Eisenfeld AJ; Sandalic L; Oldham FB; Singer JW; Ross HJ
    J Thorac Oncol; 2008 Jun; 3(6):623-30. PubMed ID: 18520802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.